Newron Pharmaceuticals SpA (XTER:NP5) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:NP5 Newron Pharmaceuticals SpA XTER:NP5
77 GF Score
Price €11.80
GF Value €14.70
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Newron Pharmaceuticals SpA  (XTER:NP5) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Newron Pharmaceuticals SpA Cyclically Adjusted PB Ratio Related Terms


Newron Pharmaceuticals SpA Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Newron Pharmaceuticals SpA's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newron Pharmaceuticals SpA Cyclically Adjusted PB Ratio Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.66 2.76 5.60 20.33

Newron Pharmaceuticals SpA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.61 4.99 5.60 4.86 20.33

XTER:NP5 vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Newron Pharmaceuticals SpA's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Newron Pharmaceuticals SpA Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Newron Pharmaceuticals SpA's Cyclically Adjusted PB Ratio falls into.


XTER:NP5
77GF Score
Newron Pharmaceuticals SpA XTER:NP5
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newron Pharmaceuticals SpA Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Newron Pharmaceuticals SpA's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Newron Pharmaceuticals SpA's adjusted Book Value per Share data for the fiscal year that ended in Dec25 was:

Adj_Book=Book Value per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=-0.535/122.6000*122.6000
=-0.535

Current CPI (Dec25) = 122.6000.

Newron Pharmaceuticals SpA Annual Data

Book Value per Share CPI Adj_Book
201612 3.154 100.300 3.855
201712 3.797 101.200 4.600
201812 3.073 102.300 3.683
201912 2.062 102.800 2.459
202012 0.966 102.600 1.154
202112 0.174 106.600 0.200
202212 -0.786 119.000 -0.810
202312 -1.676 119.700 -1.717
202412 0.073 121.200 0.074
202512 -0.535 122.600 -0.535

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Newron Pharmaceuticals SpA (XTER:NP5) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of €11.80 is trading 19.7% below its estimated GF Value™ of €14.70. GuruFocus considers Newron Pharmaceuticals SpA to be Modestly Undervalued.

Key valuation signals for XTER:NP5:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €14.70 vs. price of €11.80 (19.7% below fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the XTER:NP5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
77GF Score

Get the complete analysis for XTER:NP5

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.80
Price
€14.70
GF Value